




rPEGYLATION OF URICASE FOR REDUCED IMMUNOGENICITY




Lena Grieser,¹ Julian Schmidt,¹ Philip Dreier¹ and Holger Frey¹



¹ Department of Chemistry, Johannes Gutenberg University Mainz, 55128 Mainz, Germany




Via AROP



with



rPEGylation of Uricase



INTRODUCTION

PEGylation

Prevalence of Anti-PEG Antibodies (APAs) → Accelerated Blood Clearance (ABC)

→ Induction of APAs

→ Immune Reactions (at High APA Titer)

SYNTHESIS


	M_p^a (kDa)	GME ^{a,b} (mol%)	$\bar{D}^b$	$\bar{D}_{HPLC}^b$
mPEG ₂₄₅	10.8	0	1.19	-
rPEG ₂₁₈ ^{0.50}	14.4	50	1.22	1.08

^a Determined via MALDI-ToF (Matrix: DCTB, KTFA)


^b Determined via SEC (Eluent: DMF, Standard: PEG)



Randomized Copolymerisation of GME and EO results in rPEG.




ACTIVATION




Degree of Activation α can be quantified via UV-Vis Spectroscopy

	Eq. NPCF	α (%)
mPEG ₂₄₅ -NPC	2.2	Quant.
rPEG ₂₁₈ ^{0.50} -NPC	2.0	88



NPC Activation of rPEG is Analogously to mPEG Accessible.

CONJUGATION



First rPEGylation of Uricase was Successfully Performed.